First of all, I'm sorry you and your husband are faced with the challenges of CMT, and I wish you all the best. It looks like the studies he has participated in have followed the trend of human genetics: we started out studying candidate genes, moved to whole exomes when the technology became afforadable, and now even whole genomes can be sequenced at a reasonable price. I'm not a CMT expert, but if you are asking what's next in the trajectory of genomic research, your husband might next be asked to participate in whole genome expression studies that measure RNA. And on the more distant horizon, companies are now claiming to be working on adult human gene editing... https://www.statnews.com/2019/05/07/verve-new-crispr-company-targets-heart-disease/
I hope for your family, that these studies are fruitful, and that translational therapeutics are rapidly forthcoming!